Identifying FLT3 Mutations in AML
Identifying FLT3 Mutations in Acute Myeloid Leukemia (AML) to Inform Clinical Decision-making – A Focus on Relapsed/Refractory Disease
No continuing education (CE) or continuing medical education (CME) credit can be provided for this presentation sponsored by Astellas Pharma US, Inc.
Catherine Lai, M.D., M.P.H.
Medstar Georgetown University Hospital ; Lombardi Comprehensive Cancer Center ; Georgetown University Medical Center
*Important note: Attendees are required to view the presented slides during the virtual program
To RSVP for this program – Please contact:
Kindly reply by March 23, 2021
In the RSVP, please include your name, contact information, organization, and specialty.